{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:36:18Z","timestamp":1791200178773,"version":"4.2.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2007,3,14]],"date-time":"2007-03-14T00:00:00Z","timestamp":1173830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,3,14]],"date-time":"2007-03-14T00:00:00Z","timestamp":1173830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1245\/s10434-006-9337-9","type":"journal-article","created":{"date-parts":[[2007,3,13]],"date-time":"2007-03-13T20:13:04Z","timestamp":1173816784000},"page":"1860-1869","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":193,"title":["Gastrointestinal Perforation Due to Bevacizumab in Colorectal Cancer"],"prefix":"10.1245","volume":"14","author":[{"given":"Muhammad Wasif","family":"Saif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymen","family":"Elfiky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald R.","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,3,14]]},"reference":[{"key":"9337_CR1","unstructured":"American Cancer Society. Colorectal cancer facts and figures\u2014special edition 2005. Available at: http:\/\/www.cancer.org\/docroot\/STT\/content\/STT_1x_Colorectal_Cancer_Facts_and_Figures_-_Special_Edition_2005.asp. Accessed January 28, 2007"},{"key":"9337_CR2","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines for oncology: Colon cancer version 2.2006. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/colon.pdf. Accessed June 18, 2006"},{"key":"9337_CR3","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","volume":"20","author":"HF Dvorak","year":"2002","unstructured":"Dvorak HF. Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20:4368\u201380","journal-title":"J Clin Oncol"},{"key":"9337_CR4","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182\u20136","journal-title":"N Engl J Med"},{"key":"9337_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/35025220","volume":"407","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249\u201357","journal-title":"Nature"},{"key":"9337_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrc905","volume":"2","author":"R Kerbel","year":"2002","unstructured":"Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2:727\u201339","journal-title":"Nat Rev Cancer"},{"key":"9337_CR7","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/362841a0","volume":"362","author":"KJ Kim","year":"1993","unstructured":"Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362:841\u20134","journal-title":"Nature"},{"key":"9337_CR8","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1124\/mol.104.000638","volume":"66","author":"S Emanuel","year":"2004","unstructured":"Emanuel S, Gruninger RH, Fuentes-Pesquera A, et al. A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models. Mol Pharmacol 2004; 66:635\u201347","journal-title":"Mol Pharmacol"},{"key":"9337_CR9","first-page":"3374","volume":"59","author":"DH Gorski","year":"1999","unstructured":"Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999; 59:3374\u20138","journal-title":"Cancer Res"},{"key":"9337_CR10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3:391\u2013400","journal-title":"Nat Rev Drug Discov"},{"key":"9337_CR11","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335\u201342","journal-title":"N Engl J Med"},{"key":"9337_CR12","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1200\/JCO.2005.05.112","volume":"23","author":"FF Kabbinavar","year":"2005","unstructured":"Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23:3697\u2013705","journal-title":"J Clin Oncol"},{"key":"9337_CR13","doi-asserted-by":"crossref","unstructured":"Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin\/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: final analysis of the TREE study (abstract 3510). Paper presented at American Society of Clinical Oncology 2006","DOI":"10.1200\/jco.2006.24.18_suppl.3510"},{"key":"9337_CR14","doi-asserted-by":"crossref","unstructured":"Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200 (abstract 2). Paper presented at American Society of Clinical Oncology 2005","DOI":"10.1200\/jco.2005.23.16_suppl.2"},{"key":"9337_CR15","doi-asserted-by":"crossref","unstructured":"Saltz LB, Lenz H, Kindler H, et al. Interim report of randomized phase II trial of cetuximab\/bevacizumab\/irinotecan (CBI) versus cetuximab\/bevacizumab (CB) in irinotecan-refractory colorectal cancer (abstract 169b). Paper presented at American Society of Clinical Oncology Gastrointestinal Symposium 2005","DOI":"10.1200\/jco.2005.23.16_suppl.3508"},{"key":"9337_CR16","doi-asserted-by":"crossref","unstructured":"Hedrick E, Kozloff M, Hainsworth J, et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE) (abstract 3536). Paper presented at American Society of Clinical Oncology 2006","DOI":"10.1200\/jco.2006.24.18_suppl.3536"},{"key":"9337_CR17","doi-asserted-by":"crossref","unstructured":"Kozloff M, Hainsworth J, Badarinath S, et al. Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE) (abstract 3537). Paper presented at American Society of Clinical Oncology 2006","DOI":"10.1200\/jco.2006.24.18_suppl.3537"},{"key":"9337_CR18","doi-asserted-by":"crossref","unstructured":"Sugrue M, Kozloff M, Hainsworth J, et al. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy (abstract 3535). Paper presented at American Society of Clinical Oncology 2006","DOI":"10.1200\/jco.2006.24.18_suppl.3535"},{"key":"9337_CR19","unstructured":"Kretzschmar A, Cunningham D, Berry S, et al. Incidence of gastrointestinal perforations and bleeding in patients starting bevacizumab treatment in first-line mCRC without primary tumour resection: preliminary results from the First BEATrial (abstract 248). Paper presented at American Society of Clinical Oncology Gastrointestinal Symposium 2006"},{"key":"9337_CR20","unstructured":"Van Cutsem E, Michael M, Berry S, et al. Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI and capecitabine for mCRC: First BEATrial (abstract 250). Paper presented at American Society of Clinical Oncology Gastrointestinal Symposium 2006"},{"key":"9337_CR21","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1200\/JCO.2005.10.017","volume":"23","author":"HI Hurwitz","year":"2005","unstructured":"Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23:3502\u20138","journal-title":"J Clin Oncol"},{"key":"9337_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","volume":"21","author":"F Kabbinavar","year":"2003","unstructured":"Kabbinavar F, Hurwitz H, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60\u20135","journal-title":"J Clin Oncol"},{"key":"9337_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/sj.bjc.6602714","volume":"93","author":"W Hamilton","year":"2005","unstructured":"Hamilton W, Round A, Sharp D, Peters TJ. Clinical features of colorectal cancer before diagnosis: a population-based case-control study. Br J Cancer 2005; 93:399\u2013405","journal-title":"Br J Cancer"},{"key":"9337_CR24","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/jnci\/95.3.230","volume":"95","author":"N Gatto","year":"2003","unstructured":"Gatto N, Frucht H, Sundararajan V, et al. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst 2003; 95:230\u20136","journal-title":"J Natl Cancer Inst"},{"key":"9337_CR25","unstructured":"Beers MH, Berkow R, eds. Gastrointestinal disorders: acute abdomen and surgical gastroenterology. In: The Merck Manual of Diagnosis and Therapy. 17th ed. Whitehouse Station, NJ: Merck & Co., Inc., 1999; pp 269\u2013275"},{"key":"9337_CR26","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/0002-9610(94)90101-5","volume":"167","author":"MJ Murray","year":"1994","unstructured":"Murray MJ, Gonze MD, Nowak LR, Cobb CF. Serum d(-)-lactate levels as an aid to diagnosing acute intestinal ischemia. Am J Surg 1994; 167:575\u20138","journal-title":"Am J Surg"},{"key":"9337_CR27","doi-asserted-by":"publisher","first-page":"H547","DOI":"10.1152\/ajpheart.00616.2005","volume":"290","author":"F Baffert","year":"2006","unstructured":"Baffert F, Le T, Sennino B, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 2006; 290:H547\u201359","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"9337_CR28","doi-asserted-by":"publisher","first-page":"H509","DOI":"10.1152\/ajpheart.01075.2005","volume":"290","author":"C Betsholtz","year":"2006","unstructured":"Betsholtz C, Armulik A. Homeostatic functions of vascular endothelial growth factor in adult microvasculature. Am J Physiol Heart Circ Physiol 2006; 290:H509\u201311","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"9337_CR29","doi-asserted-by":"publisher","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","volume":"290","author":"T Kamba","year":"2006","unstructured":"Kamba T, Tam BYY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006; 290:H560\u201376","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"9337_CR30","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1097\/00005344-199606000-00011","volume":"27","author":"R Yang","year":"1996","unstructured":"Yang R, Thomas GR, Bunting S, et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 1996; 27:838\u201344","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl 3","key":"9337_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000088481","volume":"69","author":"MS Gordon","year":"2005","unstructured":"Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005; 69(Suppl 3):25\u201333","journal-title":"Oncology"},{"key":"9337_CR32","unstructured":"Genentech Inc. Avastin prescribing information. June 2006"},{"key":"9337_CR33","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/jso.20301","volume":"91","author":"FA Scappaticci","year":"2005","unstructured":"Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91:173\u201380","journal-title":"J Surg Oncol"},{"key":"9337_CR34","unstructured":"Berry S, Michael M, Kretzschmar A, et al. Lack of effect of starting bevacizumab shortly after venous access device implantation on wound healing\/bleeding complications: preliminary results from First BEAT (abstract 245). Paper presented at American Society of Clinical Oncology Gastrointestinal Symposium 2005"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-006-9337-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-006-9337-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-006-9337-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-006-9337-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T02:05:43Z","timestamp":1652839543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-006-9337-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,14]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["9337"],"URL":"https:\/\/doi.org\/10.1245\/s10434-006-9337-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,14]]},"assertion":[{"value":"1 October 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}